The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Biora Inc. | COM | 74319F107 | 5,579,088 | 42,362,097 | SH | SOLE | NA | 42,362,097 | 0 | 0 | ||
Biora Inc. | Note 7.250% 12/0 | 74319FAB3 | 56,262,773 | 103,500,000 | PRN | SOLE | NA | 0 | 0 | 103,500,000 | ||
Amryt Pharma PLC | Sponsored ADS | 03217L106 | 64,658,056 | 8,857,268 | SH | SOLE | NA | 8,857,268 | 0 | 0 | ||
Societal CDMO Inc. | Com | 75629F109 | 3,281,606 | 2,202,420 | SH | SOLE | NA | 2,202,420 | 0 | 0 | ||
CAREMAX INC | COM CL A | 14171W103 | 16,305,349 | 4,467,219 | SH | SOLE | NA | 4,467,219 | 0 | 0 | ||
RVL PHARMACEUTICALS PLC | SHS | G6S41R101 | 16,352,497 | 14,600,444 | SH | SOLE | NA | 14,600,444 | 0 | 0 | ||
Omeros Corp | NOTE 6.250%11/1 | 682143AE2 | 20,240,546 | 21,005,000 | PRN | SOLE | NA | 0 | 0 | 21,005,000 | ||
Omeros Corp | NOTE 5.250% 2/1 | 682143AG7 | 31,700,772 | 58,131,000 | PRN | SOLE | NA | 0 | 0 | 58,131,000 | ||
BridgeBio Pharma Inc. | NOTE 2.250% 2/0 | 10806XAD4 | 7,753,900 | 20,000,000 | PRN | SOLE | NA | 0 | 0 | 20,000,000 | ||
PUMA BIOTECHNOLOGY INC | COM | 74587V107 | 7,580,642 | 1,792,114 | SH | SOLE | NA | 1,792,114 | 0 | 0 | ||
Paratek Pharmaceuticals Inc. | NOTE 4.750% 5/0 | 699374AB0 | 8,213,010 | 9,000,000 | PRN | SOLE | NA | 0 | 0 | 9,000,000 |